NO20082096L - Azaindol-2-karboksamidderivativer - Google Patents

Azaindol-2-karboksamidderivativer

Info

Publication number
NO20082096L
NO20082096L NO20082096A NO20082096A NO20082096L NO 20082096 L NO20082096 L NO 20082096L NO 20082096 A NO20082096 A NO 20082096A NO 20082096 A NO20082096 A NO 20082096A NO 20082096 L NO20082096 L NO 20082096L
Authority
NO
Norway
Prior art keywords
karboksamidderivativer
azaindole
compounds
receptors
modulation
Prior art date
Application number
NO20082096A
Other languages
English (en)
Norwegian (no)
Inventor
Sven Taylor
Matthias Heinrich Nettekoven
Olivier Roche
Jean-Marc Plancher
Hans Richter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20082096L publication Critical patent/NO20082096L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20082096A 2005-11-18 2008-05-06 Azaindol-2-karboksamidderivativer NO20082096L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05110949 2005-11-18
PCT/EP2006/068206 WO2007057329A1 (en) 2005-11-18 2006-11-08 Azaindole-2-carboxamide derivatives

Publications (1)

Publication Number Publication Date
NO20082096L true NO20082096L (no) 2008-05-29

Family

ID=37903781

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082096A NO20082096L (no) 2005-11-18 2008-05-06 Azaindol-2-karboksamidderivativer

Country Status (17)

Country Link
US (1) US7622466B2 (de)
EP (1) EP1966199B1 (de)
JP (1) JP2009515926A (de)
KR (1) KR101007489B1 (de)
CN (1) CN101312969A (de)
AR (1) AR056883A1 (de)
AT (1) ATE485294T1 (de)
AU (1) AU2006314649A1 (de)
BR (1) BRPI0618692A2 (de)
CA (1) CA2629232A1 (de)
DE (1) DE602006017741D1 (de)
ES (1) ES2351940T3 (de)
NO (1) NO20082096L (de)
RU (1) RU2417226C2 (de)
TW (1) TWI325425B (de)
WO (1) WO2007057329A1 (de)
ZA (1) ZA200804257B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627221T3 (es) 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2296653B1 (de) 2008-06-03 2016-01-27 Intermune, Inc. Verbindungen und verfahren zur behandlung von entzündungserkrankungen und fibrotischen erkrankungen
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US9345247B2 (en) 2012-08-17 2016-05-24 Bayer Cropscience Ag Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
JP7598642B2 (ja) * 2018-10-12 2024-12-12 ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ ネブラスカ ホスホジエステラーゼ阻害剤
WO2020168068A1 (en) * 2019-02-13 2020-08-20 The University Of Vermont And State Agricultural College Small molecule antagonist to pacap receptor and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
MY135686A (en) 2002-06-24 2008-06-30 Schering Corp Indole derivatives useful as histamine h3 antagonists
EP1585731A2 (de) * 2002-09-18 2005-10-19 Eli Lilly And Company Histamin h3 rezeptor-antagonisten, herstellung und therapeutische verwendung
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
PT1572215E (pt) * 2002-12-20 2009-12-09 Glaxo Group Ltd Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas
FI20030556A0 (fi) * 2003-04-11 2003-04-11 Abb Oy Menetelmä ja laitteisto laivan ohjaamiseksi
US20040224952A1 (en) * 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
EP1479680A1 (de) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole-Derivative als Faktor Xa Hemmer
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CA2561628C (en) 2004-04-01 2012-05-08 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses

Also Published As

Publication number Publication date
ATE485294T1 (de) 2010-11-15
RU2417226C2 (ru) 2011-04-27
EP1966199A1 (de) 2008-09-10
BRPI0618692A2 (pt) 2011-09-06
KR20080057349A (ko) 2008-06-24
TWI325425B (en) 2010-06-01
WO2007057329A1 (en) 2007-05-24
KR101007489B1 (ko) 2011-01-12
JP2009515926A (ja) 2009-04-16
US7622466B2 (en) 2009-11-24
RU2008123728A (ru) 2009-12-27
DE602006017741D1 (de) 2010-12-02
CA2629232A1 (en) 2007-05-24
TW200804374A (en) 2008-01-16
AR056883A1 (es) 2007-10-31
ZA200804257B (en) 2009-04-29
CN101312969A (zh) 2008-11-26
AU2006314649A1 (en) 2007-05-24
EP1966199B1 (de) 2010-10-20
US20090005379A1 (en) 2009-01-01
ES2351940T3 (es) 2011-02-14

Similar Documents

Publication Publication Date Title
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
EA201000098A1 (ru) Производные хиназолинамида
IL191629A0 (en) Tricyclic amide derivatives useful for treating obesity
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
TW200612936A (en) Indole derivatives
MX2007004217A (es) Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de obesidad.
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
TW200626158A (en) Naphthaline derivatives
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
NO20080553L (no) Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
NO20080937L (no) Substituerte-3-sulfonylindazolderivater som 5-hydroksytryptamin-6-ligander
TW200637817A (en) 5-aminoindole derivatives
ATE481395T1 (de) Cyclohexylderivate
DK1745010T3 (da) Substituerede cyklohexyl-1,4-diaminderivater
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application